These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of specifications for biotechnology products--perspective from Europe. Trouvin JH Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679 [No Abstract] [Full Text] [Related]
5. Lessons from Eprex for biogeneric firms. Louët S Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539 [No Abstract] [Full Text] [Related]
6. The INN crowd. Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620 [No Abstract] [Full Text] [Related]
7. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]
8. A divided INN crowd. Schellekens H Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509755 [No Abstract] [Full Text] [Related]
9. A divided INN crowd. Eich G Nat Biotechnol; 2014 Feb; 32(2):131. PubMed ID: 24509754 [No Abstract] [Full Text] [Related]
10. A divided INN crowd. Greenwood J Nat Biotechnol; 2014 Feb; 32(2):131-2. PubMed ID: 24509753 [No Abstract] [Full Text] [Related]
11. A divided INN crowd. Chin WW Nat Biotechnol; 2014 Feb; 32(2):130. PubMed ID: 24509752 [No Abstract] [Full Text] [Related]
12. The role of the pharmaceutical industry in drug development in dermatology. Cauwenbergh G Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516 [No Abstract] [Full Text] [Related]
13. Global perspective on specifications for biotechnology products--perspective from Japan. Hayakawa T Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678 [No Abstract] [Full Text] [Related]
14. Why EMA should provide clearer guidance on the authorization of NBCDs in generic and hybrid applications. Garattini L; Padula A Expert Rev Clin Pharmacol; 2017 Mar; 10(3):243-245. PubMed ID: 27997812 [No Abstract] [Full Text] [Related]
15. Current regulatory and scientific considerations for approving biosimilars in Iran. Hadavand N; Valadkhani M; Zarbakhsh A Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077 [TBL] [Abstract][Full Text] [Related]
16. Specifications from a biotechnology industry perspective. Garnick RL Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680 [TBL] [Abstract][Full Text] [Related]
17. A proposed European pharmacopeia monograph for continuous cell lines derived drugs. Dorpema JW Dev Biol Stand; 1989; 70():113-24. PubMed ID: 2759345 [No Abstract] [Full Text] [Related]
18. Equivocal role of micelles in Eprex adverse events. Smiell JM Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347 [No Abstract] [Full Text] [Related]
19. Equivocal role of micelles in Eprex adverse events. Schellekens H; Crommelin DJ Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346 [No Abstract] [Full Text] [Related]